Loading
Life sciences · Journal article
Cellular Oncology · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Dickkopf-1 (DKK1), a secreted glycoprotein, was first characterized as an antagonist of canonical Wnt/β-catenin signaling. It is now recognized as a multifunctional regulator, acting through canonical Wnt inhibition, non-canonical Wnt branches, and Wnt-independent axes mediated by the receptor Cytoskeleton-Associated Protein 4 (CKAP4). Elevated circulating or tissue DKK1 is associated with poor prognosis across multiple malignancies and has been proposed as a diagnostic and prognostic biomarker, particularly within multi-marker panels. Yet the receptor- and context-dependent mechanisms underlying its dual effects on tumor behavior remain scattered across the literature, without a unifying explanatory framework. This review consolidates current evidence on DKK1 signaling, its diagnostic and prognostic value across cancer types, and its therapeutic targeting. It also proposes an integrative model—organized around receptor engagement, cellular source, and upstream regulatory control—to explain its context-dependent behavior in cancer. We further summarize DKK1-driven immune evasion and its convergence with resistance to checkpoint blockade and review clinical progress with DKK1-targeting agents. By linking mechanistic insight to biomarker performance, this review aims to support future efforts to validate DKK1 as a clinical biomarker and guide biomarker-driven combination therapies.